Quick Takeaways
- Pegasus Laboratories announced that the US FDA granted conditional approval to Liavium-CA1 (pregabalin chewable tablets), a first-in-class therapy for dogs with Chiari-like malformation and syringomyelia (CM/SM), a chronic neurologic condition associated with severe neuropathic pain
- Liavium-CA1 received conditional approval based on pilot study data demonstrating its ability to manage pain and clinical signs associated with CM/SM while supporting ease of administration in veterinary practice settings. Pegasus continues to evaluate the therapy in a pivotal US clinical trial following its 2025 acquisition of TriviumVet
- Liavium-CA1 will be available as beef-flavored chewable tablets in 30 mg, 90 mg, and 180 mg strengths for dogs weighing ~6.6–50 pounds. The therapy will be prescription-only and classified as a Schedule V controlled substance under US federal regulations
Why It Matters?
Liavium-CA1 gives Pegasus (PRN Pharmacal) a first-in-class, branded neurology asset in a completely underserved niche, which should support premium pricing and strong loyalty among neurologists and specialty practices that see CM/SM dogs.
Because conditional approval lets Pegasus market now while TriviumVet completes a pivotal trial, the product can start building real-world experience and revenue in a high‑need segment, while also sharpening Pegasus’ profile in advanced pain management and controlled substances, potentially paving the way for more CNS-focused veterinary products and making the company more strategically attractive over the next 3–5 years.
Source: PRnewswire
